Clinical Trial Update: A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart [Phase 1]

View source ↗

Summary

Phase 1 study of AZD5672 by AstraZeneca for rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• AZD5672 (AZD5672)

Snippet

Sponsor: AstraZeneca | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED